Xcout IntelAlector, Inc.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Subscribe to see Alector, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alector, Inc. at a glance
Alector, Inc. is a biotech company headquartered in South San Francisco, United States. It is publicly listed (ALEC) with a market capitalisation of $230.9M. Xcout tracks 20 named people at Alector, Inc., including Neil Berkley (CFO & Chief Business Officer). Xcout recorded 11 job postings from Alector, Inc. in the last 90 days.
Alector, Inc. leadership
- Neil BerkleyCFO & Chief Business Officer
- Clare HuntChief People & Places Officer
- Danielle PasqualoneGeneral Counsel
- Arnon RosenthalCo-Founder, Chief Executive Officer & Director
- Hua LongSenior Vice President and Head of Research
- Hua Long DABTSenior VP & Head of Research
14 more named people on record for Alector, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Alector, Inc.
Xcout recorded 11 job postings from Alector, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Alector, Inc.'s hiring signals →
Tech stack
Alector, Inc. competitors
A few of Alector, Inc.'s closest competitors — see the full list of competitors and alternatives →
Cortexyme, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutics for major degenerative disorders.
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
FoldLogic Bio is a clinical-stage biotechnology company developing targeted immunotherapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Multiple System Atrophy. The company focuses on modulating the central nervous system's immune responses, specifically targeting microglial activity, alpha-synuclein, and TREM2 to halt disease progression.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Amygdala Neurosciences Inc is an independent small biopharmaceutical company headquartered in San Francisco, California. Its mission is to invent and develop first-in-class therapeutics.
AriBio is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Seongnam, South Korea, with additional offices in the United States. The company focuses on developing novel therapeutics for neurodegenerative diseases.
Get Alector, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alector, Inc. in Xcout Intel
- 20 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access